Search Medical Condition
Please enter condition
Please choose location from dropdown

Bedford Park SA, Australia Clinical Trials

A listing of Bedford Park SA, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (308) clinical trials

Study to Evaluate the Safety Tolerability and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

In Part A, healthy participants will be randomized to receive a single dose application of BOS-475 or vehicle cream. Following a washout period, participants will receive 7 days of repeated dosing with BOS-475 or vehicle cream on the back, followed by 7 days of repeated dosing of BOS-475 or vehicle ...

Phase

6.65 miles

Learn More »

Daily vs Intermittent Restriction of Energy: Controlled Trial to Reduce Diabetes Risk (DIRECT)

In this randomized trial study, the investigators will compare the glycaemic health benefits of intermittent fasting (IF) versus an energy matched daily restriction (DR) approach over 18-months, and relative to a non-active intervention control (SC) in individuals at risk of type 2 diabetes. It is hypothesized that IF will result ...

Phase N/A

6.65 miles

Learn More »

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.

Phase

6.65 miles

Learn More »

Prophylactic Early PN in HPT/BMT

A standard parenteral nutrition solution will be used. The parenteral nutrition solution will be given once daily, and infused intravenously. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L). Nutritional targets will be measured using indirect Calorimetry where available, or ...

Phase N/A

6.65 miles

Learn More »

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Participants considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Phase

6.65 miles

Learn More »

The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B

There are large inter-individual differences in the bleeding pattern of patients with moderate or mild hemophilia. The major determinant of bleeding phenotype is the level of coagulant factor VIII or IX. In hemophilia A, studies addressing the association between factor VIII level and the clinical bleeding pattern yield conflicting results. ...

Phase N/A

6.65 miles

Learn More »

Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects

The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of both hospital acquired and community acquired infections. In particular, the increase in Enterobacteriaceae expressing extended spectrum beta-lactamases (ESBLs) and carbapenemases that are resistant ...

Phase

6.65 miles

Learn More »

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.

Phase

6.65 miles

Learn More »

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. The primary objective of this study is to evaluate the effect of cabozantinib in combination with nivolumab and ipilimumab ("triplet") on the duration ...

Phase

6.65 miles

Learn More »

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, ...

Phase

6.65 miles

Learn More »